drugset / Trial / NCT00004985

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985

Phase 2 Completed 75 enrolled Agouron Pharmaceuticals
Treatment

Summary

The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.

Timeline

Start
2000-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Capravirine Small molecule 1400 mg
Background Nelfinavir Other / unclassified